Cargando…

Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy

Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiki, Hiroto, Kikawa, Yuichiro, Terada, Mitsumi, Mizusawa, Junki, Honda, Michitaka, Iwatani, Tsuguo, Mizutani, Tomonori, Mori, Keita, Nakamura, Naoki, Miyaji, Tempei, Yamaguchi, Takuhiro, Ando, Masahiko, Nakamura, Kenichi, Fukuda, Haruhiko, Kiyota, Naomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991489/
https://www.ncbi.nlm.nih.gov/pubmed/36702740
http://dx.doi.org/10.1093/jjco/hyad007
_version_ 1784902166642688000
author Ishiki, Hiroto
Kikawa, Yuichiro
Terada, Mitsumi
Mizusawa, Junki
Honda, Michitaka
Iwatani, Tsuguo
Mizutani, Tomonori
Mori, Keita
Nakamura, Naoki
Miyaji, Tempei
Yamaguchi, Takuhiro
Ando, Masahiko
Nakamura, Kenichi
Fukuda, Haruhiko
Kiyota, Naomi
author_facet Ishiki, Hiroto
Kikawa, Yuichiro
Terada, Mitsumi
Mizusawa, Junki
Honda, Michitaka
Iwatani, Tsuguo
Mizutani, Tomonori
Mori, Keita
Nakamura, Naoki
Miyaji, Tempei
Yamaguchi, Takuhiro
Ando, Masahiko
Nakamura, Kenichi
Fukuda, Haruhiko
Kiyota, Naomi
author_sort Ishiki, Hiroto
collection PubMed
description Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials.
format Online
Article
Text
id pubmed-9991489
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99914892023-03-08 Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy Ishiki, Hiroto Kikawa, Yuichiro Terada, Mitsumi Mizusawa, Junki Honda, Michitaka Iwatani, Tsuguo Mizutani, Tomonori Mori, Keita Nakamura, Naoki Miyaji, Tempei Yamaguchi, Takuhiro Ando, Masahiko Nakamura, Kenichi Fukuda, Haruhiko Kiyota, Naomi Jpn J Clin Oncol Review Article (Invited) Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials. Oxford University Press 2023-01-25 /pmc/articles/PMC9991489/ /pubmed/36702740 http://dx.doi.org/10.1093/jjco/hyad007 Text en © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review Article (Invited)
Ishiki, Hiroto
Kikawa, Yuichiro
Terada, Mitsumi
Mizusawa, Junki
Honda, Michitaka
Iwatani, Tsuguo
Mizutani, Tomonori
Mori, Keita
Nakamura, Naoki
Miyaji, Tempei
Yamaguchi, Takuhiro
Ando, Masahiko
Nakamura, Kenichi
Fukuda, Haruhiko
Kiyota, Naomi
Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title_full Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title_fullStr Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title_full_unstemmed Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title_short Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
title_sort patient-reported outcome and quality of life research policy: japan clinical oncology group (jcog) policy
topic Review Article (Invited)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991489/
https://www.ncbi.nlm.nih.gov/pubmed/36702740
http://dx.doi.org/10.1093/jjco/hyad007
work_keys_str_mv AT ishikihiroto patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT kikawayuichiro patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT teradamitsumi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT mizusawajunki patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT hondamichitaka patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT iwatanitsuguo patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT mizutanitomonori patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT morikeita patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT nakamuranaoki patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT miyajitempei patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT yamaguchitakuhiro patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT andomasahiko patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT nakamurakenichi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT fukudaharuhiko patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT kiyotanaomi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy
AT patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy